/
GERN
$1.30-$0.02 (-1.52%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$846.8M
642M shares
52-week range
$1.04 – $2.01
27% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-0.17
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $460.0K | $253.0K | $1.4M | $596.0K | $237.0K | $77.0M | $183.9M |
| Cost of revenue | $12.7M | $51.3M | $50.1M | $0 | $0 | $0 | $1.3M | $4.7M |
| Gross profit | −$11.7M | −$50.8M | −$49.8M | $1.4M | $596.0K | $237.0K | $75.7M | $179.1M |
| Gross margin | -1093.5% | -11046.1% | -19683.4% | 100.0% | 100.0% | 100.0% | 98.4% | 97.4% |
| R&D | $13.4M | $52.1M | $51.5M | $85.7M | $95.5M | $125.0M | $103.7M | $73.7M |
| Operating income | −$31.1M | −$72.5M | −$76.9M | −$114.0M | −$138.6M | −$193.9M | −$173.7M | −$53.8M |
| EBITDA | −$27.0M | −$72.4M | −$76.8M | −$111.6M | −$134.2M | −$174.8M | −$154.8M | −$51.9M |
| Net income | −$27.0M | −$68.5M | −$75.6M | −$116.1M | −$141.9M | −$184.1M | −$174.6M | −$85.8M |
| Net margin | -2534.4% | -14901.7% | -29888.1% | -8335.4% | -23808.9% | -77690.7% | -226.7% | -46.7% |
| EPS (diluted) | -0.15 | -0.33 | -0.28 | -0.37 | -0.37 | -0.32 | -0.27 | -0.13 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $234M | $-0.02 | $-0.03–$-0.01 | 5 |
| 2027 | $333M | $0.07 | $0.03–$0.15 | 5 |
| 2028 | $486M | $0.19 | $-0.06–$0.62 | 5 |
| 2029 | $697M | $0.42 | $0.39–$0.50 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Geron Corp
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
www.geron.com- Employees
- 258
- IPO / List date
- Jul 31, 1996
- HQ
- FOSTER CITY, CA
Held by traders on TradeandTell
No one on the platform currently holds GERN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,799,521 | $2.7M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded GERN yet.
